Indication
Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Loading your page…
Loading your page…
Pulmonary Disease, Chronic Obstructive
Marketing Authorisation Holder: GlaxoSmithKline Trading Services Limited
EMA Authorisation: 08/05/2014
INN: umeclidinium bromide;vilanterol
AI Drug & Interaction Analysis
Free account required
Ask Osler about Anoro Ellipta (previously Anoro): drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.